OARS funding Cancer

Applications to the Fiscal Year 2017 (FY17) Peer Reviewed Cancer Research Program (PRCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The PRCRP was initiated in 2009 to provide support for research of exceptional scientific merit and is managed by the CDMRP. Appropriations for the PRCRP from FY09 through FY16 totaled $199.8 million (M). The FY17 appropriation is $60M.

Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI's research and career development. It should be clear that the proposed research is intellectually designed by the PI and not a product of the Designated Mentor. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.Key elements of the Career Development Award mechanism are as follows:* Principal Investigator: The PI must be an independent, early-career researcher or physician-scientist within 10 years after completion of his/her terminal degree (excluding time spent in residency or on family medical leave). Time spent as a postdoctoral fellow is not excluded.

The Colon Cancer Alliance Chris4 Life Research Grants in Young-Onset Colorectal Cancer Research represent an effort to encourage and support researchers to conduct young-onset colorectal cancer research and to establish a successful career path in this field. The research proposed for funding may be as follows: basic, translational, clinical, or epidemiological in nature; and should focus on changes in the microbiome and its impact in the development of young onset colorectal cancer.

The American Association for Cancer Research is accepting applications for its AACR-Bayer Innovation and Discovery Grants program, which is designed to provide new treatment options for cancers with high unmet medical need, encourage innovation and translation of ideas from basic research into novel drugs, and foster collaborations between excellent academic groups and the pharmaceutical industry.

The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).

This opportunity allows for young investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as a prostate cancer researcher of the future. The postdoctoral investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary Mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary Mentor with a more robust track record in prostate cancer research and mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a prostate cancer researcher. The PI must outline an individualized, prostate cancer-focused researcher development plan. The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PI's development as an independent prostate cancer researcher. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PI's institution can be mitigated through collaboration(s) with other institutions.

A major focus of the Network must be placed on the acquisition and distribution of specimens in limited supply, such as: * Castration-resistant disease, metastatic disease, primary untreated "de novo" metastatic disease as defined by STAMPEDE or high-risk disease defined by CHAARTED, tumors of the aggressive variant phenotype * Disproportionately affected populations, defined by ethnicity or health service access (safety net, rural, settings) * Active surveillance populations * Longitudinal/sequential specimens The Network must also collect, store, and manage data derived from the distributed biospecimens, including images of the hematoxylin and eosin (H&E)-stained samples. Applications should describe how the development of the Network biorepository will enable the prostate cancer research community to address the FY17 PCRP Overarching Challenges and FY17 PCRP Focus Areas by utilizing Network biospecimens. Applications should propose a clearly defined mission that will guide the proposed Network's biospecimen collection, distribution, and data collection processes. The Network will consist of three to five Pathology Resource Sites and a Coordinating Center, which will also function as one of the Pathology Resource Sites. These organizations will be jointly responsible for developing and maintaining the biorepository for prostate cancer research.

If the proposed project does not address any of the Overarching Challenges, the application should describe how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care. Proposed projects may include basic, translational, or clinical research, including clinical trials, but must demonstrate clinical relevance. The potential impact of the proposed research is expected to be near-term and it must be significant and go beyond an incremental advance. To maximize the potential for impact, investigators are strongly encouraged to incorporate the following components into their study design where appropriate: authentication of proposed cell lines; statistical rigor of preclinical animal experiments. As such, the PCRP-funded Prostate Cancer Biorepository Network (PCBN)

he Idea Development Award also emphasizes the potential impact, both short-term and long-term, of the research project on prostate cancer research and/or patient care. To maximize the potential for impact, investigators are strongly encouraged to incorporate the following components into their study design where appropriate: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; incorporation of experiments to assess clinical relevance and translatability of findings. As such, the PCRP-funded Prostate Cancer Biorepository Network (PCBN)

the application must describe how the project will nevertheless address a critical disparity-related need in the field of prostate cancer research and/or patient care. The Health Disparity Research Award also emphasizes the potential impact, both short-term and long-term, of the research project in reducing or eliminating prostate cancer health disparities. To maximize the potential for impact, investigators are strongly encouraged to incorporate the following components into their study design where appropriate: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; incorporation of experiments to assess clinical relevance and translatability of findings. As such, the PCRP-funded Prostate Cancer Biorepository Network (PCBN) (http://www.prostatebiorepository.org) and/or the North Carolina - Louisiana Prostate Cancer Project (PCaP) (http://www.ncla-pcap.org) are important resources to consider if retrospectively collected human anatomical substances or correlated data are critical to the proposed studies. Studies utilizing data derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and that apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged.

The FY17 PRCRP Idea Award with Special Focus supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. The "Special Focus" of this award mechanism is on exposures, conditions, or circumstances that are unique to the military, disproportionately represented in a military beneficiary population, or may affect mission readiness. Cancers or circumstances with cancer risk that may affect military families are of special importance to the care and well-being of the military for total mission readiness. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System is critical to active duty Service members, Veterans, other military beneficiaries, and the American public.

The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries. The studies should be hypothesis-driven and multidisciplinary approaches are encouraged. Investigators are encouraged to leverage the data already collected by the registries to investigate the determinates of health disparities. The goal of these analyses will be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.

The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries. The studies should be hypothesis-driven and multidisciplinary approaches are encouraged. Investigators are encouraged to leverage the data already collected by the registries to investigate the determinates of health disparities. The goal of these analyses will be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.

The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries. The studies should be hypothesis-driven and multidisciplinary approaches are encouraged. Investigators are encouraged to leverage the data already collected by the registries to investigate the determinates of health disparities. The goal of these analyses will be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.

The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries. The studies should be hypothesis-driven and multidisciplinary approaches are encouraged. Investigators are encouraged to leverage the data already collected by the registries to investigate the determinates of health disparities. The goal of these analyses will be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.

Applications to the Fiscal Year 2017 (FY17) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The LCRP was initiated in FY09 to promote innovative and competitive research focused on the development of integrated disciplines to identify, treat, and manage early curable lung cancer (excluding mesothelioma).

Applications to the Fiscal Year 2017 (FY17) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The LCRP was initiated in FY09 to promote innovative and competitive research focused on the development of integrated disciplines to identify, treat, and manage early curable lung cancer (excluding mesothelioma).

Applications to the Fiscal Year 2017 (FY17) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The LCRP was initiated in FY09 to promote innovative and competitive research focused on the development of integrated disciplines to identify, treat, and manage early curable lung cancer (excluding mesothelioma).

The Surveillance Research Program (SRP) within the Division of Cancer Control and Population Sciences (DCCPS) and the Prevention, Control and Population Sciences Branch (PCPSB) within the Office of Acquisitions (OA), National Cancer Institute, National Institutes of Health, intends to solicit the Surveillance, Epidemiology, and End Results (SEER) Program.